Apogee Leads the Industry with Excellence in Customer Service

Apogee’s Clients Reward Exceptional Service with High NPS

ATLANTA, Nov. 18, 2020 (GLOBE NEWSWIRE) — Apogee Interactive, Inc., a leading provider of customer engagement software for the energy industry, announced today their utility customers awarded the Software as a Service (SaaS) company with a Net Promoter Score of 49. This score reflects 15 points higher than the industry average of 34 in the category of software and application companies and an improvement of 13 points from last year’s score. Net Promoter Score (NPS) is a widely used customer loyalty and advocacy metric that measures customers’ willingness to recommend a company and return for another purchase. Therefore, NPS correlates with the quality of the company’s customer relationships, the superiority of its service, and its customers’ willingness to promote the firm to others and expand their services.

Net Promoter Scores are based on responses to a single standardized question: How likely is it that you would recommend our company/product/service to a friend or colleague? NPS can be as low as −100 (all detractors) or as high as +100 (all promoters). Compared to software companies reporting NPS, Apogee’s score of 49 is “excellent.” This score reflects the company’s continued dedication and investment in their customers’ satisfaction. NPS score of 49 shows a strong presence of customer goodwill and providing utilities with cutting-edge customer engagement tools.

Susan Gilbert, Apogee’s CEO, and co-founder, reports, “Outstanding service and cutting-edge innovation are the hallmarks of Apogee’s corporate culture and are integral to our business strategy. As a team, we pride ourselves on knowing we are delivering world-class energy analysis and extraordinarily effective customer engagement software that “future-proofs” our clients’ decisions to engage our services.”

Over the firm’s 27 years serving the energy industry, Apogee’s growth has been fueled by achieving a 98% customer retention rate, growing existing accounts, and by adding new major clients each year. Apogee has proudly established itself as the unparalleled best choice for utilities seeking a turn-key solution for customer engagement, driving customer satisfaction, educating customers, and influencing their behavior.

About Apogee Interactive:

Apogee Interactive is the nation’s leading full-service provider of proactive customer engagement software services for utilities. Serving the utility industry since 1993, Apogee’s digital engagement platform is used by hundreds of North American utilities from coast to coast, including some of the largest and most progressive, such as Southern Company, Consolidated Edison, Lakeland Electric, and Jackson EMC. For more information visit, www.apogee.net or on LinkedIn.

Media Contact: Karen Morris, 678-684-6801 or [email protected]



Canada Goose Commits to Keeping the Planet Cold and the People on It Warm with Launch of HUMANATURE

Canada Goose Commits to Keeping the Planet Cold and the People on It Warm with Launch of HUMANATURE

Brand Announces Purpose Platform and Unveils Its Most Sustainable Parka to Date

TORONTO–(BUSINESS WIRE)–
Today, Canada Goose (NYSE:GOOS, TSX:GOOS) introduces HUMANATURE, its purpose platform that unites its sustainability and values-based initiatives. This purpose commitment is embedded across every aspect of the company’s operations. Keeping the planet cold through its Sustainable Impact Strategy, and people warm by honouring and invigorating communities, prioritizing philanthropic endeavors and building culture through the arts. HUMANATURE is the driving force of Canada Goose’s enduring purpose commitment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005303/en/

The Standard Expedition Parka (Photo: Business Wire)

The Standard Expedition Parka (Photo: Business Wire)

“The role of business has evolved – in today’s world, driving meaningful change is just as important as the bottom line,” said Dani Reiss, President & CEO of Canada Goose. “We are steadfast in our commitment to strengthening our communities, protecting our planet and working towards a future for generations to come. Since 1957, we have been trusted to protect people from the elements and to keep them warm; now, through HUMANATURE, we are taking warmth to an even deeper societal level.”

Keeping the Planet Cold

Canada Goose has a decades long tradition of being a sustainably led company with its lifetime warranty and commitment to making its core products in Canada. The brand unveiled its Sustainable Impact Strategy in April, building on these core values and outlining its vision for the future. The brand continues to transform the way it does business – with sustainability at the forefront, while remaining dedicated to its function-first design.

In January 2021, Canada Goose will debut its most sustainable parka to date, the Standard Expedition Parka. The Standard, inspired by the iconic Expedition Parka, will help set the standard for the future of outerwear at Canada Goose. The Standard is made from recycled and undyed fabrics, lining and interlining, 100 per cent responsibly sourced down and reclaimed fur. The Standard Expedition Parka exemplifies the brand’s strategy and commitment to sustainability; the design generates 30 per cent less carbon, based on footprint, compared to the in-line Expedition Parka.

“Innovation is at the core of everything we do. Our approach is driven by constant improvement – testing, learning, improving – while ensuring we deliver on our commitment to quality and functionality. We innovate for the betterment of our consumers and our planet,” said Woody Blackford, EVP, Product of Canada Goose. “We’ve turned our commitments into action in under a year. The Standard Expedition Parka is just the beginning for where we will take the brand.”

Sustainable Impact

Strategy

  • Commit to net zero direct and indirect (Scope 1 and 2) greenhouse gas emissions by 2025
  • Achieve 100 per cent RDS Certification by 2021
  • Commit to 90 per cent bluesign® approved products by 2025
  • Eliminate single-use plastics in all Canada Goose owned or controlled facilities by the end of 2020

Standard Expedition

Parka

Canada Goose’s most sustainable parka to date, made from recycled and undyed fabrics, lining and interlining, 100 per cent responsibly sourced down and reclaimed fur. The Standard Expedition Parka generates 30 per cent less carbon, based on footprint, when compared to the in-line Expedition Parka.

Sustainable Apparel

Coalition (SAC)

Canada Goose joined the SAC, alongside over 250 sustainability leaders across the industry. SAC provides a suite of sustainability measurement tools included within the Higg Index, to drive environmental and social responsibility throughout the brand’s supply chain.

Polar Bears International

(PBI)

The people, wildlife and landscapes of the North are of vital importance – what happens there affects the global population. Since the launch of the Canada Goose PBI collection 13 years ago, the brand has contributed more than $3.5 million to the organization.

Students on Ice (SOI)

SOI and Canada Goose have a shared mandate of inspiring and catalyzing initiatives that contribute to global sustainability, diversity and inclusion; the epitome of HUMANATURE.

Keeping People Warm

For decades, Canada Goose has built a reputation for warmth. The lifestyle brand’s apparel enables human survival in the outdoors – whether its snow, rain, wind or cold – so that people can thrive in the elements and focus on the experience at hand. Drafting off this legacy, HUMANATURE will now galvanize Canada Goose’s approach to its longstanding social initiatives.

“Canada Goose is engrained in the global community and the cultural zeitgeist. We celebrate people and artists around the world, spanning continents, mediums and industries, including filmmakers, designers and visual artists,” said Penny Brook, CMO of Canada Goose. “Our passion for communities, both outside and within our brand, is strongly represented in HUMANATURE – and further reinforces that it is a mindset and a way of being.”

Canada Goose Resource

Centre Program

What began as the donation and delivery of left-over Canada Goose fabric and materials to Inuit communities in the North, has expanded to also include the donation of repurposed parkas, many upcycled from the Canada Goose warranty program. The parkas will keep Northern communities warm, while keeping the planet cold and deliver against its sustainability commitments.

Project Atigi

This annual social entrepreneurship project was born in the North. Canada Goose partners with Inuit designers to create capsule collections, with proceeds benefitting Inuit Tapiriit Kanatami (ITK), the national voice of Inuit in Canada. To date, the brand has donated over $175,000 to ITK.

Response Program

At the onset of COVID-19, Canada Goose pivoted from manufacturing parkas to medical gowns and scrubs, doing its part to protect the people who protect us. The company donated 14,000 units across Canada and 20,000 units to Mount Sinai in New York. As of Fall 2020, Canada Goose delivered more than 2.5 million additional units, all produced at cost, to address both provincial and federal contracts.

Inclusivity

Canada Goose embraces diversity in all its forms and definitions, striving to remove barriers to create an inclusive culture and equitable workplace where everyone can live authentically. To further embolden this, the brand’s Inclusion Advisory Council is a unified body that acts as thought leaders and advisors on matters of inclusion within the internal community.

HUMANATURE Pass

The HUMANATURE Pass is a benefit available to full-time corporate Canada Goose employees. This one-hour, weekly pass encourages employees to set aside time during business hours to connect with nature. The program also benefits retail employees who receive a complimentary jacket and accessory in lieu of the pass.

Underrepresented Voices in Film

Canada Goose connects people through stories. Part of its six-decade journey has been spent on film sets, playing a supporting role in the magic of making movies, acting as a warm companion on a cold set. Canada Goose celebrates underrepresented voices and how they transport storytelling to screen. Canada Goose has delivered $350,000 in bursaries and awards to support underrepresented voices across the film industry.

In Residence

In Residence is a program by the community, for the community. The brand provides local artists with a global stage to share their story and express the spirit of their community through dynamic installations in-store, bringing HUMANATURE to life.

Northern Art Program

Canada Goose has pursued a rich art program in its global retail locations. The program is focused on elevating Canadian and Arctic narratives, prioritizing Inuit art that expresses the kinship between person and land – the ultimate representation of HUMANATURE. With over 275 artworks on display in over 25 stores, the Canada Goose Northern Art Collection is now the largest retail collection of Inuit art in the world.

To learn more about HUMANATURE, visit the HUMANATURE page.

About Canada Goose

Founded in a small warehouse in Toronto, Canada in 1957, Canada Goose has grown into one of the world’s leading makers of performance luxury apparel. Every collection is informed by the rugged demands of the Arctic and inspired by relentless innovation and uncompromised craftsmanship. From the coldest places on Earth to global fashion capitals, people are proud to wear Canada Goose products. Canada Goose is a recognized leader for its Made in Canada commitment, and is a long-time partner of Polar Bears International. Visit www.canadagoose.com for more

Courtney LaRue

Manager, Communications

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Fashion Philanthropy Retail Luxury Other Retail Environment Other Philanthropy

MEDIA:

Photo
Photo
“Than and Now” by Aoudla Pudlat in Canada Goose’s Mall of America Store (Photo: Business Wire)
Photo
Photo
“Story Tree” by Alex Fisher and Qavavau Manumi in Canada Goose’s Yorkdale Shopping Centre Store (Photo: Business Wire)
Photo
Photo
“Sedna and Young” by Pootoogook Jaw in Canada Goose’s Paris Store (Photo: Business Wire)
Photo
Photo
The Standard Expedition Parka (Photo: Business Wire)

Neurologist and Psychiatrist Prof. Johannes Rolf Streffer, MD Joins AC Immune SA as Chief Medical Officer

Prof.
Streffer
is
a
n
established
authority on
n
euroscience
and
b
iomarker modalities

Appointment
re
affirm
s
AC Immune’s
scien
tific
leadership
in neurodegeneration

LAUSANNE, Switzerland, Nov. 18, 2020 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that Prof. Johannes R. Streffer, an authority on neurology and psychiatry, was hired as the Company’s Chief Medical Officer, and he is expected to join the Company in January 2021.

Prof. Streffer joins AC Immune from UCB Biopharma SPRL where he currently holds the position of Vice President, Head of Translational Medicine Neuroscience. His expertise will further accelerate AC Immune’s progress in advancing its pipeline of therapies targeting neurodegenerative diseases.

Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “We welcome Prof. Streffer’s timely appointment, as his understanding of biomarkers and experience of clinical study design in Alzheimer’s disease (AD), and particularly preclinical AD, will positively impact AC Immune’s discovery efforts. His appointment is a further affirmation of our scientific leadership in the neurodegenerative disease field. Prof. Streffer’s significant expertise and standing in the scientific and medical community will be an invaluable asset as we work to develop innovative treatments for neurodegenerative diseases using our proprietary technology platforms.”

Prof
.
Streffer
commented: “I am humbled and proud to be invited to join AC Immune, an established pioneer at the forefront of discovering and developing treatments for neurodegenerative diseases. It is tremendously exciting to be involved at the cutting edge of research addressing an area with such a high unmet medical need and where my work on clinical studies and understanding early biomarkers in Alzheimer’s could play a critically important role. The existing and developing pipeline of AC Immune is very impressive. I look forward to working with the outstanding team at AC Immune and hope my own expertise will contribute to their continued success.”

At UCB Prof. Streffer led the development of a translational space in neuroscience, integrating clinical and biomarker sciences. Prior to this he was a member of the Alzheimer Disease Area Leadership Team at Janssen, Pharmaceutical Companies of Johnson & Johnson. Here he gained experience in early experimental AD trials, including biomolecular modalities such as positron emission tomography (PET), volumetric and functional MRI, genetics, cognition and cerebrospinal fluid markers. As a member of the Experimental Medicine group and as leader of the Janssen BACE inhibitor (BACEi) program targeting Alzheimer’s Disease he initiated a number of methodological and biomarker studies focusing on early diagnosis and translation. Prof. Streffer was also the industrial lead for European Medical Information Framework (EMIF)-AD. In the Innovative Medicines Initiative (IMI)-EMIF program researchers from 14 countries combined in a EUR 56 million project to integrate a wide variety of AD data cohorts to foster understanding of early biomarkers and change in the predementia AD spectrum.

Prof. Streffer is a graduate of the University of Tübingen, Germany, where he received his medical degree. He also completed graduate studies on neuro-oncology and is Board certified in psychiatry and neurology. He has published more than 70 manuscripts and is a visiting Professor in the Department of Biomedical Sciences at the University of Antwerp.

About AC Immune SA

AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigenTM and MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent, and modify neurodegenerative diseases caused by misfolding proteins. The Company’s pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company and Janssen Pharmaceuticals.

For further information, please contact:

Head of Investor Relations

Joshua Drumm, Ph.D.
AC Immune
Phone: +1 917 809 0814
Email: [email protected]
US Media

Katie Gallagher
LaVoie HealthScience
Phone: +1 617 792 3937
Email: [email protected]
   
Global Head of Communications

Judith Moore
AC Immune
Phone: +41 79 826 63 82
Email: [email protected]
European Investors & Media

Chris Maggos
LifeSci Advisors
Phone: +41 79 367 6254
Email: [email protected]

Forward looking statements

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.



Organicell Announces Additional Site for Phase I/II Clinical Trial of Zofin™ for Treatment of COVID-19

Organicell Announces Additional Site for Phase I/II Clinical Trial of Zofin™ for Treatment of COVID-19

MIAMI–(BUSINESS WIRE)–
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it is now enrolling patients at an additional site, Larkin Hospital North located in Hialeah, Florida for its Phase I/I clinical trial for the use of its Zofin™ therapeutic in treatment of COVID-19.

This multi-center, randomized, double-blinded, placebo-controlled phase I/II clinical trial is being conducted to investigate the safety and potential efficacy of intravenous infusion of Zofin™ for the treatment of moderate to severe acute respiratory syndrome (SARS) related to COVID-19. The study will be enrolling 20 participants. As of November 17, 2020, several patients have already begun treatment at Larkin Hospital South, located in South Miami, Florida.

“The addition of this clinical trial site is another step towards determining whether to apply for FDA approval for the use of Zofin™ as a COVID-19 treatment, and increases our capacity for participating patients in order to finalize this clinical trial by year’s end,” said Albert Mitrani, Chief Executive Officer of Organicell.

“To date, we have successfully enrolled several patients who have begun treatment in this trial, with no reported serious adverse events. We are looking forward to continued progress as we enroll additional patients in the coming weeks. Most of all, we are eager to begin enrollment at Larkin Community Hospital North this week,” said Dr. Luis Mendez-Mulet, Infectious Disease Specialist at Alternative Research Associates and Larkin Community Hospital.

“We are excited to sign on Larkin Hospital North as a second clinical trial site. We look forward to working with their research team as we advance our trial for using Zofin™ to treat moderate to severe acute respiratory syndrome due to COVID-19,” said Dr. Maria Ines Mitrani, Chief Science Officer of Organicell.

About Organicell Regenerative Medicine, Inc.:

Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company that harnesses the power of nanoparticles to develop innovative biological therapeutics for the treatment of degenerative diseases. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Based in South Florida, the Company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Maria Ines Mitrani, Chief Science Officer. To learn more, please visit https://organicell.com/.

About Larkin Hospital

Larkin Community Hospital is an integrated healthcare delivery system accredited by the Joint Commission with locations in South Miami, Hialeah and Hollywood, Florida. Our network of acute care hospitals provides a complete continuum of healthcare services, including a full range of inpatient and outpatient services, home health agencies, Skilled Nursing facilities, Rehab centers and Assisted Living facilities in Miami-Dade and Broward County. To learn more, please visit http://larkinhospital.com/.

About Zofin™:

Zofin™ is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues. Zofin™ is currently being tested in a phase I/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin™ for the treatment of moderate to SARS related to COVID-19 infection vs placebo.

Forward-Looking Statements:

Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as “will,” “believes,” “expects,” “potential” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties, including the risk factors discussed in the Company’s periodic reports that are filed with the SEC and available on the SEC’s website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.

Jeffrey Freedman

RooneyPartners

646-432-0191

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Health Infectious Diseases Hospitals Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

Grown Rogue Prepares to Launch Nitrogen Sealed Flower Jars in Michigan While Continuing Bay City Expansion; Commences Sungrown Sales and Expands Indoor Facility in Oregon; Grants Options and Issues Shares

Grown Rogue Prepares to Launch Nitrogen Sealed Flower Jars in Michigan While Continuing Bay City Expansion; Commences Sungrown Sales and Expands Indoor Facility in Oregon; Grants Options and Issues Shares

MEDFORD, Ore.–(BUSINESS WIRE)–Grown Rogue International Inc. (“Grown Rogue” or the “Company”) (CSE: GRIN) (OTC: GRUSF), a multi-state cannabis company with operations and assets in Oregon and Michigan, is excited to announce the pending launch of its Certified Fresh Nitrogen Sealed Jars—designed to ensure fresh, connoisseur-quality premium cannabis—into the Michigan market. Improvements at the Bay City facility, operated by the Company’s Michigan partner Golden Harvests, LLC, continues with the construction of an additional 2,000 sq. ft. flowering room and dedicated cloning and genetic housing rooms to increase vegetative area to support the additional flowering canopy. Also, sun grown sales in Oregon are commencing after a successful harvest and the Company is completing the final build out of its Medford facility with the addition of 2,500 sq. ft. of flowering canopy.

Grown Rogue is launching its Certified Fresh Nitrogen Sealed 3.5 gram Jars at select Michigan retailers providing consumers with three popular cultivars to choose from; Rogue OG, Strawberries & Cream and White Cookies. Grown Rogue’s unique jars contain hand selected flower that are vacuum sealed and nitrogen injected, similar to their patented pre-roll process to remove oxygen that degrades flower while locking in maximum freshness and terpenes. Strong retail and consumer demand are leading the Company to expand the number of cultivars and accounts in which the jars will be available over the coming months.

“We are excited to launch our Nitrogen Sealed Jars into the Michigan market,” said Obie Strickler, Grown Rogue’s Chief Executive Officer. “Many retailers have been transitioning more of their business to pre-packaged flower so this is a perfect time to bring our nitrogen sealed jars to the Michigan market allowing us to control the quality and freshness consumers have come to expect from the Grown Rogue brand. Our flower is not only pre-packaged, but nitro sealed to lock in freshness so consumers can be confident that when they ‘pop the top’ on one of our jars the flower will be certified fresh.”

In Oregon, Grown Rogue recently completed a record sun grown harvest. The Company grew 18 unique cultivars at its two farms which are in the process of being dried, cured and trimmed. Initial sun grown sales are commencing with an expected average price of US$900/lb, which is an increase of 30% over the average price point for the 2019 sun grown harvest. Grown Rogue has also entered into strategic pre-sale contracts in which vendors have paid the Company up front for future sales between US$800 and US$1,000 per pound. The Company is also completing the build out of its indoor facility in Medford, OR, which will add 2,500 sq. ft. of flowering capacity while increasing veg capacity from 1,200 sq. ft. to 1,400 sq. ft. The buildout is expected to be completed by the end of January 2021. Grown Rogue estimates that the additional growth will deliver US$1M of incremental revenue on an annual basis, with a buildout cost of approximately US$200,000 and variable margins on the additional sales anticipated to exceed 60%.

The Company has also announced that it has issued a total of 240,908 common shares to certain directors and employees of the Company relating to amounts owed for services rendered. In addition, the Company issued 25,000 common shares to an existing member of Golden Harvests, LLC in connection with the extension of the next payment of cash and shares owed under the terms of the option agreement with Golden Harvests, LLC, as previously announced on August 11, 2020. The above mentioned common shares were issued at a price of $0.11 per share. The Company has also granted options to purchase an aggregate of 200,000 common shares of the Company (the “Stock Options”) to an employee. The Stock Options are exercisable at a price of $0.15 per share for a period of four years from the date of issuance. The common shares described above and the common shares underlying the Stock Options are subject to a four month hold period expiring on March 19, 2021.

Insiders of the Company received an aggregate of 210,908 common shares of the Company. The Company has relied on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in section 5.5(b) and 5.7(a) of MI 61-101 in respect of such insider participation.

About Grown Rogue

Grown Rogue International (CSE: GRIN | OTC: GRUSF) is a vertically-integrated, multi-state Cannabis family of brands on a mission to inspire consumers to “enhance experiences” through cannabis. We have combined an expert management team, award winning grow team, state of the art indoor and outdoor manufacturing facilities, and consumer insight based product categorization, to create innovative products thoughtfully curated from “seed to experience.” The Grown Rogue family of products include sungrown and indoor premium flower, along with nitro sealed indoor and sungrown pre-rolls and jars.

FORWARD LOOKING STATEMENTS

This press release contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities. Forward‐ looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions and include information regarding: (i) statements regarding the future direction of the Company (ii) the ability of the Company to successfully achieve its business and financial objectives, (iii) plans for expansion of the Company into Michigan and securing applicable regulatory approvals, and (iv) expectations for other economic, business, and/or competitive factors. Investors are cautioned that forward‐looking information is not based on historical facts but instead reflect the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combined company. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; and in particular in the ability of the Company to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and cannabis products in the markets that the Company operates in; adverse changes in applicable laws; or adverse changes in the application or enforcement of current laws; compliance with extensive government regulation and related costs, and other risks described in the Company’s public disclosure documents filed on www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law.

SAFE HARBOR STATEMENT

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company’s financing plans; (ii) trends affecting the Company’s financial condition or results of operations; (iii) the Company’s growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors including the risk disclosed in the Company’s Form 20-F and 6-K filings with the Securities and Exchange Commission.

The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational cannabis marketplace in the United States through its indirect operating subsidiaries. Local state laws where its subsidiaries operate permit such activities however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Company’s business are disclosed in the Company’s Listing Statement filed on its issuer profile on SEDAR at www.sedar.com. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

For further information on Grown Rogue International please visit www.grownrogue.com or contact:

Obie Strickler

Chief Executive Officer

[email protected]

Investor Relations Desk Inquiries

[email protected]

(458) 226-2100

KEYWORDS: United States North America Oregon Michigan

INDUSTRY KEYWORDS: Packaging Tobacco Specialty Manufacturing Alternative Medicine Health Retail Agriculture Natural Resources

MEDIA:

Logo
Logo

Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (ECCLOCK®) in Japan by its Development Partner, Kaken Pharmaceutical

Kaken
plans
to launch ECCLOCK

®

for the treatment of primary axillary hyperhidrosis
in Japan on November 26, 2020

– – –

ECCLOCK

®

placed
on Japan’s National Health Insurance (NHI) drug reimbursement price list

BOULDER, Colo., Nov. 18, 2020 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its Japanese development partner, Kaken Pharmaceutical Co., Ltd. (“Kaken”) plans to launch sofpironium bromide gel, 5% under the brand name ECCLOCK® in Japan for the once daily treatment of primary axillary (underarm) hyperhidrosis on November 26, 2020. In addition, ECCLOCK® has been placed today on Japan’s National Health Insurance (NHI) drug reimbursement price list. The NHI listed drug price for ECCLOCK® in Japan is ¥243.70 per gram, which is ¥4,874.00 (USD $46.47) for a 20 gram bottle or approximately a two-week supply.

“We are excited to announce the reimbursement and planned commercial launch of ECCLOCK® in Japan, which is the first topical prescription product to be approved and marketed there for the treatment of primary axillary hyperhidrosis,” said Robert Brown, Chief Executive Officer of Brickell. “A key step to Kaken’s moving forward with the planned commercial launch of ECCLOCK® in Japan was their receipt of the reimbursement price listing by the NHI. Kaken is now well-positioned to launch ECCLOCK® in Japan on November 26 as an important novel, first-in-class therapy for the millions of Japanese patients suffering with this debilitating medical condition.”

On September 25, 2020, Kaken received approval from the Japanese Pharmaceuticals and Medical Devices Agency to manufacture and market ECCLOCK® for the once-daily treatment of primary axillary hyperhidrosis.

Under the sublicense agreement with Kaken, Brickell is entitled to receive sales-based milestone payments, as well as tiered royalties based on a percentage of net sales of ECCLOCK® in Japan. Furthermore, Kaken has rights to develop and commercialize sofpironium bromide in Korea, China and certain other Asian countries.

Sofpironium bromide is currently being developed by Brickell in the U.S. for the treatment of primary axillary hyperhidrosis. Brickell recently initiated its pivotal Phase 3 clinical program in the U.S., which is comprised of two pivotal Phase 3 clinical trials (Cardigan I and II) to evaluate the safety and efficacy of sofpironium bromide gel, 15% compared to vehicle (placebo) in approximately 350 subjects (per trial) aged nine years and older with primary axillary hyperhidrosis. Brickell expects to report topline data from both the Cardigan I and II studies in the fourth quarter of 2021.

About Sofpironium Bromide

Sofpironium bromide is a proprietary investigational new chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are designed to exert their action topically and are potentially rapidly metabolized into a less active metabolite once absorbed into the blood.  Sofpironium bromide was discovered at Bodor Laboratories, Inc. by Dr. Nicholas Bodor D.Sc., d.h.c. (multi), HoF, Graduate Research Professor Emeritus, University of Florida.

About Hyperhidrosis

Hyperhidrosis is a life-altering medical condition where a person sweats more than the body requires to regulate its temperature. More than 15 million people, or 4.8% of the population of the United States, and 12.76% of the population in Japan, are believed to suffer from hyperhidrosis1,2. Primary axillary (underarm) hyperhidrosis is the targeted first indication for sofpironium bromide and is the most common site of occurrence of hyperhidrosis, affecting an estimated 65% of patients with hyperhidrosis in the United States. Additional information can be found on the International Hyperhidrosis Society website: https://www.sweathelp.org/.

About Brickell

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit https://www.brickellbio.com.

Cautionary Note Regarding Forward-Looking Statements

Any statements made in this press release relating to future financial, business and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such matters, including without limitation, the anticipated timing, scope, design and/or results of ongoing and future clinical trials, intellectual property rights, including the validity, term and enforceability of such, the expected timing and/or results of regulatory approvals and prospects for commercializing any of Brickell’s product candidates, or research collaborations with, or actions of, its partners, including in Japan, the United States or any other country, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict,” “potential,” “look forward” and similar expressions and their variants, as they relate to Brickell, Kaken, AnGes or any of Brickell’s partners, may identify forward-looking statements. Brickell cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including without limitation, ability to obtain adequate financing to advance product development, ability to maintain and enforce intellectual property rights, potential delays for any reason in product development, regulatory changes, supply chain disruptions, unanticipated demands on cash resources, any disruption to its business caused by the current COVID-19 pandemic, interruptions, disruption or inability by Kaken to supply, launch and commercialize the product in Japan, or obtain or retain adequate pricing or reimbursement, and other risks associated with developing, and obtaining regulatory approval for and commercializing product candidates.

Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Brickell’s filings with the United States Securities and Exchange Commission (SEC), which are available at https://www.sec.gov (or at https://www.brickellbio.com). The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements.
                                
1Doolittle et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 2016; 308: 743-749.
2 Fujimoto et al. Epidemiological study and considerations of focal hyperhidrosis in Japan. J Dermatol 2013; 40: 886-90.

Brickell Investor Contact:

Dan Ferry
LifeSci Advisors
(617) 430-7576
[email protected]

 



Nubeva Releases Modern Next-Gen Decryption Library

Decryption Library Enables Manufacturers of Security and Monitoring Tools to Rapidly Support TLS 1.3 and 1.2 ECDH Based Decryption Algorithms

SAN JOSE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) — Nubeva Technologies Ltd. (TSX-V: NBVA), a developer of decryption software that broadens network traffic visibility, today announced the release of a next-generation TLS Decryption Library. This industry-first software solution enables deep packet inspection of network traffic through the decryption of the newest TLS (SSL) traffic, including TLS 1.3 and 1.2 with Elliptic Curve Diffie-Hellman Ephemeral (ECDHE) protocols at extremely high speeds and efficiency. The library enables security and monitoring solution manufacturers to rapidly support modern decryption algorithms previously not available in the industry.

“Our new Decryption Library was created based on customer demand,” said Randy Chou, CEO at Nubeva. “Enterprise security and application monitoring teams require total visibility into their network traffic to monitor anomalies and identify security risks. Nubeva’s decryption library provides an easy, low-cost way to conduct deep packet inspection and identify and respond to issues.”

Available to license with existing software, Nubeva’s decryption library operates at extreme speed – in excess of 15 gigabytes per second per single CPU core on general purpose hardware. The solution scales up to easily support 40 and 100 gig appliances, and it can scale out in parallel to support in excess of Terabit/sec speeds, all at breakthrough price-performance points.

“This is the first-of-its-kind high-performance decryption library that seamlessly plugs into existing security and monitoring software systems,” said Steve Perkins, Chief Marketing Officer at Nubeva. “It can be deployed in online systems such as web gateways and firewalls to add high performance, wire-speed level decryption. Or, it can be used in passive monitoring systems to add support for the latest protocols that have blinded many of these solutions.”

The Decryption Library works with Nubeva’s Symmetric Key Intercept (SKI) software. SKI delivers a breakthrough method for the decryption of modern TLS traffic in support of deep packet inspection systems and services. An alternative to legacy man-in-the-middle, proxy termination, and passive intercept methods, SKI technology discovers session (symmetric) keys from clients or servers during the TLS session and securely transports them to security and application monitoring tools to use to unlock and inspect the data within. SKI allows systems to see into more traffic with far greater price performance advantages, and provides absolute simplicity to implement and operate. The new Decrypt Library expands the Nubeva SKI offering by providing an advanced, high-speed decryption solution that works with TLS symmetric session keys from Nubeva or any other source.

Released in 2019, Nubeva Symmetric Key Intercept is currently licensed by several solution providers. The new Decryption Library is available now.

About Nubeva Technologies Ltd. 

Nubeva Technologies Ltd. has changed the decrypted visibility game with pure, symmetric decryption. Nubeva helps enterprises gain the visibility needed through decryption so they can fully inspect network traffic. The need to inspect data in motion is fundamental to network security and application monitoring and assurance. The shift to SaaS, the cloud, and stronger encryption practices like perfect forward secrecy and TLS 1.3, create new and unique challenges for in-line and out-of-band decryption and visibility solutions. Nubeva re-imagined TLS visibility and created a new solution for the modern era of strong encryption in dynamic and distributed compute environments. Visit nubeva.com for more information.

Forward-Looking Statements 
This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the Company’s business plans and the outlook of the cybersecurity industry. Although the Company believes in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, its subsidiaries, their securities, or their respective financial or operating results (as applicable).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

For additional information, please contact: 

Nubeva Technologies Ltd.       
Steve Perkins, Chief Marketing Office       
1-(844)538-4638

Chuck Grothaus
[email protected]
612-770-0026



Visa Expands Fast Track Program to Enable Next Generation of Fintechs to Rebuild the Global Economy

Visa Expands Fast Track Program to Enable Next Generation of Fintechs to Rebuild the Global Economy

Visa adds new Partner Toolkit and Visa Ready Fintech Enabler certification to Fast Track program

Fast Track program grows 360% year-over-year, supports accelerating industries including digital wallets, financial inclusion, business-to-business (B2B) and digital currency payments

SAN FRANCISCO–(BUSINESS WIRE)–
The COVID-19 pandemic has created major financial challenges for businesses and consumers alike. As money management becomes increasingly digital, fintechs play a pivotal role in helping to restore and rebuild the global economy. To provide increased support for the ecosystem, Visa (NYSE: V) today announced two new components of its fintech Fast Track program:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005362/en/

(Graphic: Business Wire)

(Graphic: Business Wire)

1. A rich Partner Toolkit to help fintechs accelerate their growth and better serve their customers.

2. A certification program called Visa Ready for Fintech Enablers, which makes it easier for fintechs to quickly connect with certified1 partners for digital issuance and other key services.

Fintech leaders around the world are increasingly choosing to work with Visa across key categories including digital wallets, digital banking, ‘Buy Now, Pay Later’, B2B payments, cross-border remittance, bill payments, payments infrastructure, and person-to-person payments. Recent examples of fintechs partnering with Visa include Affirm, BillGO, Finix, Gojek,PayPal, Rappi, Stripe, Varo Bank, and Venmo, among many others.

With the expansion of Visa’s industry leading Fast Track program, fintechs are armed with the tools to become category winners. Fast Track participation has grown 360% year-over-year, and Visa has welcomed hundreds of fintechs2 who are actively engaged in the program.

“It’s thrilling to see fintech partners utilize our programs and network to digitize financial services and improve the lives of the consumers and businesses they touch,” said Terry Angelos, SVP and Global Head of Fintech, Visa. “Through the Fast Track program, we’re providing fintechs with a simple set of tools to bring their products to life. The resources we provide, such as online licensing and card design, have helped make Fast Track the leading program for fintechs.”

Introducing the Fast Track Partner Toolkit

Visa has introduced a Fast Track Partner Toolkit designed specifically for fintech partners who onboard with the program. The toolkit was created to accelerate a company’s growth and provides extraordinary access to Visa’s experts in strategy, marketing, design, risk management, and more. Through the toolkit, partners can leverage educational resources like payments boot camps to help upskill a company’s knowledge of the industry, tap into key strategic resources to craft customized benchmarking studies and utilize Visa’s online card design tools to help build and launch a card into market quickly.

Powering the Digital Issuance Journey with Visa Ready

Visa Ready certification for “Fintech Enablers” is designed to help technology companies build and launch payment solutions that meet Visa’s global standards around security and functionality. These companies are in turn helping fintechs around the world build their own products by providing the solutions and expertise they need to get up and running.

Available today, Visa Ready for Fintech Enablers establishes a certified ecosystem of partners who are experts in the capabilities fintechs need to launch and operate products effectively on the Visa network. Recently, the Visa Ready program has added new partners from across the globe— from Sao Paulo to Singapore. New certified processing partners include BPC Radar Payments (Global), Conductor (LAC), FIS (Global), Global Processing Services (GPS) (Global), i2c (Global), Marqeta (Global), and NovoPayment (LAC, NA). Similarly, Visa has certified BIN sponsors across the world that help stand up programs for fintechs including Dock (LAC), Nium (APAC, EU), Railsbank (APAC, EU) and Sutton Bank (NA).

Fast Track Experiences

Of the hundreds of global companies now part of the program, some of the most recent innovators to join Fast Track include:

  • Digital Wallets: Working with companies like Careem Pay, LINE Pay, Nubi, Paga, PalmPay, Razer, and Vipps, Visa is expanding access to digital payments by meeting evolving consumer preferences for managing their money – and transforming some formerly closed-loop systems limited to certain geographies or functionalities into open ones, giving users greater choice, security and utility.
  • Advancing Financial Inclusion and Social Impact: Ensuring that consumers and businesses in all parts of the world have access to the financial tools and products to improve their lives is core to Visa’s mission. Companies like CapWay are helping to bring underrepresented communities access to digital payments, while Cuenca provides free accounts that can be opened in under 5 minutes. Daylight is a digital banking platform focused on improving the financial lives of the 30M+ LGBT+ in the U.S. and the first fintech in the U.S. to focus specifically on the LGBT+ community. MPOWER Financing and X1 are pioneering new methods of extending credit to demographics like undergrads and international students. SoLo Funds aims to provide affordable loans for Americans who live paycheck to paycheck, and Tomorrow aims to bring change to the mobile banking sector through its commitment to climate protection, sustainability and economic change.
  • B2B Payments: Visa is transforming B2B payments, a segment that represents $120 trillion in opportunity3, in its work with Fast Trackmembers in every corner of the world, including: Airwallex, Checkbook.io, GMO-Payment Gateway, Konfio, and Payhawk.
  • Digital Currency Advancement: Visa is working closely with companies likeBlockFi, Crypto.com, eToro Money, Fold, Ternio.io, Zap and ZenGo to connect digital currencies and its existing network of 61 million merchants.
  • New Enablement Partners: Fast Track is made possible due to collaborations with enablement partners who lay the foundation for fintechs to build their products. Announced today, Galileo, i2c, and Peoples Trust, are becoming part of Fast Track in Canada, joining a class of over 25 enablement partners around the world. From LAC, Visa has new partners like Cacao that offer BIN sponsorship, issuer processing, and program management.

Comments from Partners:

“Today’s digitally-savvy businesses and consumers expect a modern and centralized experience when managing and paying bills — a process that’s been locked in the past with inefficient systems,” said Mike Pinto, EVP Enterprise Alliances & Product, BillGO. “When it comes to paying bills, everyone expects instantaneous payments and with Visa we are further extending our ability to offer real-time frictionless bill pay.”

“The mission behind CapWay has always been to provide more financial opportunity, access, and education, particularly for those who have been underserved and overlooked by the traditional banking system,” said Sheena Allen, CEO, CapWay. “We knew Visa was the right partner for our team for reasons outside of the fact that they provide the technology and payments prowess. More importantly, we share the same commitment to social impact that underpins the work we do each day at CapWay, and they have been fully supportive in our work to provide a solution as we are entering a predominately cashless economy.”

“Becoming part of programs like Fast Track and Visa Ready has allowed us to connect with new companies in the ecosystem and help them realize their product visions without compromise,” said Amir Wain, CEO and Founder, i2c. “It’s clear that these programs were built to meet the specific needs of today’s fintechs both large and small and will help everyone in the ecosystem thrive with the tools and partners needed to get to market as quickly, and easily as possible.”

“Giving everyone choice in how and where they pay is essential to our mission of providing people and businesses around the world with access to simple, secure and reliable digital payments,” said Jim Magats, SVP Omni Payments, PayPal. “We’re excited to be partnering with Visa to advance the future of digital payments and help even more customers get faster access to their funds.”

“2021 will be a year when Rappi builds even more opportunities for couriers (Rappitenderos), restaurant partners and small businesses. We face a lot of challenges ahead, but through collaboration, entrepreneurship and technology, we’re going to get through them and create progress in our region,” said Simon Borrero, CEO and co-founder, Rappi. “Working with a partner like Visa has been key for us in creating new opportunities across financial services for our partners and users. Visa technology is one of the most recognized in the world and we are proud to be able to have their support as a trusted brand in the markets where we have our digital wallet, as it is only the first step to raise the standard of financial services in Latin America and the Caribbean.”

“This is a difficult time for millions of consumers and their communities,” said Colin Walsh, CEO, Varo Bank. “We are proud to be working with partners like Visa to ensure our customers have fast, secure access to their money, and safer payment options like tap-to-pay and mobile wallets, as well as a shared commitment to innovation that will power the future of banking.”

“Today, the ability to pay digitally is no longer just a convenience but a necessity and with Vipps being the leading digital wallet in Norway, reaching 3.8 million users, we are core to ensuring citizens are able to send, pay and receive money at the touch of a button,” said Rune Garborg, CEO, Vipps. “With Visa, we are enabling issuing banks to offer smarter and simplified digital payment services to their customers in Europe and beyond. Together with Visa, we are able to leverage our joint expertise, and experience to give consumers and businesses access to secure, digital commerce, regardless of where they live or what mobile device they have.”

For more information on Visa programs and resources built for the fintech community, visit here.

About Visa Inc.

Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network – enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of digital commerce on any device for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit About Visa, visa.com/blog and @VisaNews.


1 Visa Ready partners are vetted and certified based on a specific set of criteria including, but not limited to, their ability to support digital issuance, ability to support multi-tenant architecture and ability to manage risk, among other capabilities.

2 Visa Fast Track Global Data, September 2020

3 Visa Q4 2020 Earnings Call Transcript

Visa Inc.

Caylah Novak

[email protected]

831-431-3454

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Professional Services Technology Finance Software Banking Internet

MEDIA:

Photo
Photo
(Graphic: Business Wire)

DoubleVerify Announces Next Evolution of Brand Safety & Suitability: Brand Suitability Tiers

DV is the first to align with standards from the 4A’s Advertising Protection Bureau (APB) & WFA’s Global Alliance for Responsible Media (GARM)

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — DoubleVerify (“DV”), a leading software platform for digital media measurement, data and analytics, today announced that it will release the next evolution of its brand safety and suitability solution: Brand Suitability Tiers. This new offering, available as of January 2021, will allow brands to align suitability settings with their own unique standards, maximizing precision and scale.

With Brand Suitability Tiers, advertisers will have access to 13 categories of content tiered by three levels of risk. Content risk is determined by both content type (e.g., educational, news, dramatic depiction, user-generated) and topic. The consideration of content type alongside content topic will enable DV clients to exercise increased control over their brand safety and suitability preferences. In total, DV clients will be able to take advantage of 89 unique Brand Safety and Suitability settings offering the most comprehensive and flexible coverage available in the market.

With this release, DV will become the first verification company to align product functionality with the Brand Safety Floor and Brand Suitability Framework advanced by the 4A’s Advertising Protection Bureau (APB) and World Federation of Advertisers (WFA) Global Alliance for Responsible Media (GARM). Built with the aim of strengthening current contextual brand safety practices and developing shared language, these standards help the industry implement brand suitability guidelines specific to each advertiser’s unique preferences.

“By calibrating our brand safety and suitability solution with the 4As and WFA, we’re making it possible for advertisers, publishers and platforms to speak a common, consistent language,” said Matt McLaughlin, COO of DoubleVerify. “As brand safety and suitability needs continue to evolve, this alignment is critical and will benefit the industry at large.”

“Advertisers demand clarity and flexibility into the content and context adjacent to their online promotion,” said Joe Barone, Managing Partner Brand Safety Americas for GroupM. “We applaud DV’s initiative to standardize brand suitability tiering in line with the framework advanced by the 4A’s and GARM — helping to accelerate buyer transparency and confidence.”

Brand Suitability Tiers leverage the policy-driven approach that has guided DV’s category development over the past decade. DV created comprehensive classification policies for each category and each risk tier, with meaningful differentiation between them. As such, classification remains clear and actionable for advertisers. Moreover, Brand Suitability tiers draw on DV’s proven Semantic Science engine and machine learning technology, incorporating new concepts as they enter the news cycle.

As a part of the release of Brand Suitability Tiers, DV will offer even greater transparency into its content classification, giving advertisers access to comprehensive reports detailing the category dimensions of all their impressions. Advertisers can use these insights to directly measure brand safety and suitability impact and optimize media plans accordingly.

For more information about DoubleVerify, contact [email protected]

About
DoubleVerify

DoubleVerify is a leading software platform for digital media measurement, data, and analytics. DV’s mission is to be the definitive source of transparency and data-driven insights into the quality and effectiveness of digital advertising for the world’s largest brands, publishers, and digital ad platforms. DV’s technology platform provides advertisers with consistent and unbiased data and analytics that can be used to optimize the quality and return on digital ad investments. Since 2008, DV has helped hundreds of Fortune 500 companies gain the most from their media spend by delivering best in class solutions across the digital advertising ecosystem, helping to build a better industry. Learn more at www.DoubleVerify.com.



Contact: [email protected]

Medicenna Announces Upcoming Oral Presentations at the 2020 Society for Neuro-Oncology Annual Meeting

TORONTO and HOUSTON, Nov. 18, 2020 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will be presenting two on-demand oral presentations as part of the 2020 Society for Neuro-Oncology (SNO) Annual Meeting, which is being held virtually from November 19-21, 2020.

The presentations will include data and analyses from the MDNA55-05 trial, a recently completed Phase 2b trial evaluating MDNA55 in recurrent glioblastoma multiforme (rGBM) patients. Following completion of this trial and an End of Phase 2 Meeting, the United States Food and Drug Administration (FDA) has agreed that Medicenna can conduct an innovative open-label hybrid Phase 3 trial that allows for the use of a substantial number of subjects (two-thirds) from a matched external control arm to support regulatory approval of MDNA55 for rGBM. This trial design should provide the opportunity to accelerate the timelines and reduce the costs when compared with a traditional randomized control arm.

Details of the on-demand oral presentations are below:

Abstract ID: CTIM-13
Title: Clinical efficacy of MDNA55, an interleukin-4 receptor targeted immunotherapy, in recurrent GBM delivered by convection enhanced delivery (CED)
Session Name: Clinical Trials Session II
Speaker: Dr. John Sampson, MD, PhD, MHSc, MBA, Robert H. and Gloria Wilkins Distinguished Professor and Chair of Neurosurgery, Duke University School of Medicine

Abstract ID: NIMG-28
Title: Validation of modified response assessment in neuro oncology (mRANO) determined PFS as a strong predictor of overall survival in recurrent glioblastoma treated with a targeted immunotoxin
Session Name: Surgery, Radiation, Imaging Session I
Speaker: Dr. Benjamin M. Ellingson, PhD, Director of the UCLA Brain Tumor Imaging Laboratory (BTIL), Co-Director of the Center for Computer Vision and Imaging Biomarkers, Member of the UCLA Brain Tumor Program, UCLA Health

The on-demand oral presentations will be available for viewing by conference attendees online here beginning on November 19, 2020 at 9:00 AM ET. Slides from the presentations will be posted to the “Events and Presentations” page of Medicenna’s website following the conference.

About Medicenna

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines for the treatment of a broad range of cancers. Medicenna’s long-acting IL2 Superkine asset, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity and therefore preferentially stimulates cancer killing effector T cells and NK cells when compared to competing IL-2 programs. It is anticipated that MDNA11 will be ready for the clinic in 2021. Medicenna’s lead IL4 Empowered Superkine, MDNA55, has completed a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer. MDNA55 has been studied in five clinical trials involving 132 subjects, including 112 adults with rGBM. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively. For more information, please visit www.medicenna.com.

Forward-Looking Statement

This news release contains forward-looking statements under applicable securities laws and relate to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects”, “believes” and similar expressions. All statements other than statements of historical fact, included in this release, including the anticipated timing as to when MDNA11 will be ready for the clinic, that an external control arm will reduce the development costs and timelines and the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the annual information form of the Company dated May 14, 2020 and in other filings made by the Company with the applicable securities regulators from time to time in Canada and the United States.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect and that study results could change over time as the study is continuing to follow up all subjects and new data are continually being received which could materially change study results. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by Canadian and United States securities law.


Further Information

For further information about the Company please contact:

Elizabeth Williams, Chief Financial Officer, 416-648-5555, [email protected]


Investor Contact

For more investor information, please contact:

Dan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, [email protected]